Welcome to our dedicated page for EchoIQ news (Ticker: ECHQF), a resource for investors and traders seeking the latest updates and insights on EchoIQ stock.
News for ECHOIQ LTD (ECHQF) focuses on its activities as an AI and medical technology company working in cardiology. Company announcements describe how Echo IQ uses AI-driven, proprietary software to support clinical decision making based on echocardiogram data, with particular emphasis on heart failure and severe aortic stenosis.
Recent news highlights the clinical validation of EchoSolv HF, Echo IQ’s heart failure clinical decision support software, conducted through the Mayo Clinic Platform’s Validate program. This validation used an independent dataset of around 17,000 echocardiogram studies and is described by the company as the final clinical requirement before submitting EchoSolv HF for FDA 510(k) clearance. Updates also discuss the company’s intention to use its presence in the US market to drive adoption of EchoSolv HF following potential regulatory clearance.
Other announcements cover EchoSolv AS, an AI-powered clinical decision support system for severe aortic stenosis. Echo IQ reports on investigator-initiated studies and large real-world analyses presented at the American Heart Association Scientific Sessions, which examine gaps in current standard-of-care and the potential for EchoSolv AS to support more accurate identification of high-risk AS patients, including in specific subgroups such as women and low-gradient cases.
Investors and healthcare observers can also find updates on Echo IQ’s participation in industry conferences, such as the Piper Sandler Annual Healthcare Conference, and company-hosted webinars that provide overviews of study results, regulatory plans, and commercial progress. This news feed offers a central view of Echo IQ’s disclosed milestones in validation, research presentations, and market-facing activities related to its EchoSolv cardiology software.
Echo IQ (ASX:EIQ) completed an independent clinical validation of its heart failure decision support software EchoSolv HF with the Mayo Clinic Platform using ~17,000 echocardiogram studies.
The model met its primary endpoint, delivering a sensitivity of 99.5% and a specificity of 91.0%. Completion of this validation is described as the final clinical requirement before a planned FDA 510(k) submission, which Echo IQ expects to lodge in the coming weeks. The company plans to leverage its US footprint to drive uptake if FDA clearance is achieved. A webinar is scheduled for 26 November 2025 at 11:00am AEDT.
Echo IQ (ASX:EIQ / OTC:ECHQF) announced that CEO Dustin Haines will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 12:50 p.m. ET at the Lotte New York Palace.
The event will be webcast and is authorised for release by the company's board. Contact details for investor enquiries are provided for Andrew Grover and Six Degrees Investor Relations.
Echo IQ (OTC:ECHQF) highlighted two studies presented at AHA Scientific Sessions 2025 showing gaps in diagnosing and treating severe aortic stenosis (AS) and potential benefits of EchoSolv AS. A 30,878-echocardiogram investigator study found EchoSolv identified severe AS phenotypes more accurately than cardiologists and improved the male:female diagnosis ratio from 2.2:1 to 1.1:1. A separate real-world analysis of 1.18 million echocardiograms from NEDA linked to national health data found only 36% of women and 45% of men with moderate-to-severe AS received intervention and that “watchful waiting” was associated with substantial life-years lost. EchoSolv AS has FDA clearance and is positioned as a decision-support tool to reduce diagnostic delays and improve intervention timing.